View Older Stories View More Recent Stories
-
Bausch Health (BHC) Files Supplement to Proxy Statement
-
Bausch Health Announces Filing of Supplement to Proxy Statement
-
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
-
Bausch Health Announces Adoption of Shareholder Rights Plan
-
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
-
Bausch Health (BHC) Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxi
-
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide ge
-
Bausch Health Companies (BHC) PT Lowered to $8.50 at RBC Capital
-
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
-
Bausch Health to Announce First Quarter Results on April 30
-
Increasing unusual call option volume: PLNT MGA EWG XLB KDB BWA KBE ACHC WOOF BHC
-
Bausch Health Co. Inc. (BHC) Prices Upsized $4.4B Notes Offering
-
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
-
Bausch Health (BHC) Announces Conditional Redemption of Senior Notes
-
Bausch Health Announces Conditional Redemption of Senior Notes
-
Raymond James on Bausch Health Companies (BHC): 'we would expect to see a positive reaction in the stock during the next days'
-
Bausch Health Co. Inc. (BHC) Launches Syndication of New Senior Secured Credit Facilities
-
Bausch Health Co. Inc. (BHC) Launches Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
-
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
-
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
-
Bausch Health (BHC) Announces Next Steps in Financing Initiative with J.P. Morgan
-
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
-
Bausch Health Co. Inc. (BHC) Tops Q4 EPS by 2c; offers guidance
-
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
-
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
-
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
-
Jefferies Downgrades Bausch Health Companies (BHC) to Hold
-
Bausch Health Provides Update on Strategic Alternatives
-
Increasing unusual put option volume: AMTM SLS IRM JBLU NEP CAH HOG BHC DB XRX JNPR
-
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
-
Bausch Health Co. (BHC) Statement on Selection of XIFAXAN for Inflation Reduction Act's Medicare Negotiation Program
-
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
-
Bausch Health (BHC) Reports to Rumors of a Potential Sale of Bausch + Lomb
-
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
-
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
-
Bausch Health Co. Inc. (BHC) Appoints Jonathan Sadeh as EVP, Chief Medical Officer and Head of R&D
-
Bausch Health Appoints New Chief Medical Officer and Head of R&D
-
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Compl
-
Bausch Health Companies (BHC) PT Raised to $11 at RBC Capital
-
Bausch Health Co. Inc. (BHC) Misses Q3 EPS by $1.26, provides guidance
-
Bausch Health Announces Third Quarter 2024 Results
-
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
-
Bausch Health Co. (BHC) Rejects Bondholders' Debt Proposals - WSJ
-
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
-
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
-
Bausch Health Companies (BHC) PT Raised to $10 at Jefferies
-
Bausch Health Co. Inc. (BHC) large option transactions as share price up 12%
-
Bausch Health (BHC): Health Canada Approves CABTREO Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
-
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
-
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
